List of Excipients in Branded Drug CEFTAZIDIME AND DEXTROSE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
B Braun Medical Inc	CEFTAZIDIME AND DEXTROSE	ceftazidime	0264-3143	DEXTROSE
B Braun Medical Inc	CEFTAZIDIME AND DEXTROSE	ceftazidime	0264-3143	WATER

Ceftazidime and Dextrose Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: September 6, 2026

Ceftazidime and dextrose injection is a mature sterile generic product with limited compound-patent exposure and substantial opportunity in formulation execution, container technology, hospital workflow, and supply reliability. The main technical challenge is maintaining ceftazidime stability in an aqueous dextrose vehicle while controlling pH, degradation, particulate formation, container interaction, and infusion usability. Commercial differentiation is more likely to come from ready-to-use presentation, extended stability, low waste, and reliable availability than from a new active-ingredient patent.

What is the ceftazidime and dextrose product?

Ceftazidime is a third-generation cephalosporin administered parenterally for susceptible serious bacterial infections, including infections caused by Pseudomonas aeruginosa. Dextrose is used as the aqueous vehicle, commonly as a 5% dextrose injection solution.

A commercial product may be supplied as:

• A dry ceftazidime powder requiring reconstitution with dextrose solution.
• A ready-to-use premixed solution.
• A pharmacy bulk package.
• A flexible intravenous container.
• A frozen or refrigerated presentation.
• A vial paired with a separate diluent container.

The reference labeling for ceftazidime injection identifies compatibility with several intravenous fluids, including dextrose injection, but the permitted storage period depends on concentration, container, temperature, preparation method, and sterility controls (FDA, 2024a).

Ceftazidime is generally supplied as ceftazidime pentahydrate. The active ingredient is highly water soluble, but aqueous stability is affected by pH, temperature, oxygen exposure, concentration, and storage duration. Degradation can produce inactive cephalosporin-related products and must be controlled through validated stability studies.

What excipients are appropriate for ceftazidime and dextrose injection?

The preferred formulation is usually deliberately simple. The core excipient system consists of water for injection, dextrose, and pH adjustment agents when needed.

Formulation component	Function	Key development issue
Ceftazidime pentahydrate	Active pharmaceutical ingredient	Assay, degradation, particulate control
Dextrose monohydrate or anhydrous dextrose	Isotonic vehicle and energy source	Concentration, osmolality, chemical stability
Water for injection	Sterile solvent	Endotoxin, bioburden, container compatibility
Sodium hydroxide or hydrochloric acid	pH adjustment	Local pH variation and degradation risk
Nitrogen headspace, where applicable	Oxygen reduction	Container and process compatibility
Container closure system	Sterility and product protection	Sorption, extractables, leachables, moisture and oxygen transmission

The formulation should avoid unnecessary excipients. Preservatives are generally unsuitable for large-volume intravenous products unless specifically justified. Antioxidants, chelating agents, surfactants, or buffers may introduce compatibility, toxicity, regulatory, or extractables concerns.

Dextrose concentration should be selected against the intended clinical use. A 5% dextrose vehicle is familiar to hospitals and supports standard infusion workflows, but it increases the importance of osmolality, moisture transmission, and heat exposure controls. The finished product should be assessed for pH, osmolality, clarity, color, visible and subvisible particles, sterility, bacterial endotoxins, extractables, leachables, and degradation products.

How should the excipient strategy address ceftazidime stability?

The principal development objective is to reduce hydrolytic and thermal degradation without compromising infusion compatibility.

pH control

Ceftazidime stability is pH-dependent. The developer should identify the pH range that balances chemical stability, infusion tolerability, and compatibility with the dextrose vehicle. A formulation that relies on uncontrolled pH drift may show acceptable initial assay but fail during extended storage.

The development program should measure:

• Initial and final pH.
• Assay and related substances.
• Ceftazidime degradation products.
• Color change.
• Precipitation and particulate matter.
• Container closure integrity.
• Stability after simulated shipping.

A narrow pH target is usually preferable to a heavily buffered system because excess buffer can increase ionic strength, complicate compatibility, and create additional regulatory justification.

Temperature control

Ceftazidime and dextrose products should be tested under refrigerated, controlled-room-temperature, accelerated, and excursion conditions. Thermal stress can accelerate cephalosporin degradation and cause visible color changes in dextrose-containing solutions.

The product profile should distinguish among:

1. Shelf life before first use.
2. Stability after removal from refrigeration.
3. Stability after puncture or connection to an infusion set.
4. Stability after admixture with other agents.
5. Stability during transport and hospital storage.

A longer room-temperature period can have greater commercial value than a marginally longer refrigerated shelf life because hospitals often prioritize products that can move directly into automated dispensing and ward stock systems.

Oxygen and container effects

Oxygen exposure, headspace volume, closure permeability, and light transmission should be assessed. Flexible polyolefin containers can reduce breakage risk and support ready-to-use products, but they require extractables and leachables testing. Multilayer films can improve oxygen and moisture barriers but may increase manufacturing complexity.

Glass vials provide strong barrier properties but require reconstitution and create additional preparation steps. The commercial choice depends on the target setting:

• Hospitals with centralized pharmacy operations may accept vial-based products.
• Emergency departments and smaller hospitals may value ready-to-use bags.
• Home infusion providers may prioritize extended stability and compact packaging.
• Government and group purchasing contracts may prioritize cost and supply continuity.

What formulations are protected by patents?

The active ceftazidime compound has no meaningful remaining primary patent barrier in the United States. The original ceftazidime patent dates to the late 1970s and expired many years ago. Ceftazidime is therefore a mature generic small-molecule opportunity rather than a new-molecular-entity opportunity.

Potentially relevant intellectual property may still arise from:

• Specific premixed ceftazidime and dextrose compositions.
• Stabilized aqueous solutions.
• Concentrated formulations.
• Freeze-dried presentations.
• Flexible container systems.
• Dual-chamber bags.
• Manufacturing processes.
• Storage protocols.
• Combination products with other antibacterials.
• Device-assisted reconstitution or infusion systems.

A formulation patent would need claims that distinguish the product through a defined composition, concentration, pH, stability profile, container, process, or use. Broad claims covering ceftazidime in dextrose are vulnerable to prior-art challenges because ceftazidime compatibility with common infusion solutions has long been described in labeling and technical literature.

The strongest potential patent position would normally come from a narrow but commercially important combination of:

• A defined ceftazidime concentration.
• A specified dextrose concentration.
• A controlled pH range.
• A validated room-temperature stability period.
• A particular flexible container or multilayer film.
• A manufacturing process that limits degradation.

Even then, patent value depends on whether the claimed attributes are difficult for competitors to design around and whether they are listed or otherwise enforceable against a competing product.

What is the Orange Book status of ceftazidime and dextrose?

Ceftazidime and dextrose is a generic injectable product, not a biologic. It does not carry biosimilar substitution issues, and its primary regulatory pathway is an abbreviated new drug application or, depending on the presentation, another FDA application pathway.

The practical Orange Book analysis should separate three categories:

Issue	Commercial significance
Original ceftazidime compound patent	Expired; no current barrier
Product-specific formulation patents	Potentially relevant only if listed and enforceable
FDA exclusivity	Unlikely to provide a meaningful barrier for a mature injectable product

A product-specific ANDA may be subject to Paragraph IV certification if an Orange Book-listed patent exists for the relevant reference product. However, an ANDA applicant is more likely to encounter formulation and regulatory risk than an active compound-patent barrier.

For a specific product, the Orange Book review should be performed against the exact reference NDA, dosage form, route, strength, and listed patents. Different ceftazidime presentations may have different regulatory records. FDA Orange Book listings do not automatically establish that every ceftazidime-and-dextrose presentation has the same patent profile (FDA, 2025).

When does ceftazidime lose exclusivity?

Ceftazidime lost its original small-molecule exclusivity decades ago. The remaining commercial question is whether a particular premixed formulation, container, process, or device has a later patent or regulatory exclusivity period.

A practical exclusivity timeline is:

Milestone	Status
Ceftazidime discovery and original patenting	Historical
Original compound patent expiry	Long expired
Generic injectable development	Established market
Current market access	Primarily dependent on ANDA approval, manufacturing capacity, and procurement
New premixed formulation opportunity	Potentially protectable through formulation, process, or container claims
Biosimilar exclusivity	Not applicable

A new ceftazidime and dextrose formulation would not obtain new-molecular-entity exclusivity merely because it uses a new container or excipient strategy. Any regulatory exclusivity would depend on the specific FDA approval pathway and the nature of the innovation.

What Paragraph IV challenges and patent litigation affect the product?

Paragraph IV litigation risk is likely to be limited for the legacy ceftazidime molecule but can arise for a newer branded premixed presentation or proprietary delivery system.

Potential litigation triggers include:

• An ANDA applicant certifying that a listed formulation patent is invalid.
• A reference-product sponsor alleging infringement by a ready-to-use bag.
• Disputes over whether a formulation patent is properly listed.
• Claims involving stability, concentration, pH, or container structure.
• Hatch-Waxman litigation after a Paragraph IV notice.

The commercial impact of a Paragraph IV challenge depends on whether the listed patent covers the product itself or only a narrow method of use. A narrow method-of-use patent may have limited relevance if the generic label can omit the patented indication. A formulation patent that covers the exact premixed product presents a greater launch risk.

No biosimilar litigation framework applies because ceftazidime is a chemically synthesized small molecule. The relevant competitors are generic injectable manufacturers, contract manufacturers, and branded hospital-product suppliers.

How strong is the patent estate for ceftazidime and dextrose?

The legacy patent estate is weak for blocking a standard ceftazidime injection in dextrose. The opportunity to create defensible IP is stronger around the product platform than around the active ingredient.

IP category	Strength for standard product	Opportunity for new product
Ceftazidime compound patent	Very low	None
Dextrose vehicle	Very low	None
Basic ceftazidime-dextrose admixture	Low	Limited
Controlled-pH formulation	Low to moderate	Moderate
Extended room-temperature stability	Moderate if technically demonstrated	High
Dual-chamber delivery system	Moderate	High
Multilayer flexible container	Moderate	Moderate
Manufacturing process	Moderate	Moderate
Ready-to-use hospital workflow	Usually not patent-protected	High commercial value
Method of use	Low for broad antibacterial use	Limited and indication-specific

The most defensible strategy is to combine patent protection with trade secrets covering raw-material controls, compounding order, oxygen management, sterilization, filling, and container sealing. Trade-secret value is highest where the process produces a measurable stability advantage that competitors cannot easily reproduce.

What commercial opportunities exist for a ceftazidime and dextrose product?

The market opportunity is concentrated in operational improvements.

Ready-to-use intravenous bags

A ready-to-use product can eliminate pharmacy reconstitution, reduce compounding labor, and lower preparation errors. This is particularly relevant for emergency care, intensive care, smaller hospitals, and home infusion.

The product should be evaluated against:

• Nursing preparation time.
• Pharmacy batch-production requirements.
• Beyond-use dating.
• Refrigerated versus room-temperature storage.
• Infusion-set compatibility.
• Waste from unused doses.
• Unit-dose packaging.
• Barcode and serialization requirements.

Extended stability

Extended stability can support hospital inventory management and reduce product disposal. A product that remains stable for a commercially useful period at controlled room temperature can compete more effectively than a product that requires continuous refrigeration.

Stability claims must be supported by formal data rather than inferred from short-term compatibility studies. The relevant evidence includes long-term, accelerated, photostability, in-use, transport, and container-closure studies under applicable ICH and FDA expectations (ICH, 2003; FDA, 2024b).

Supply-chain reliability

Ceftazidime is an established injectable antibiotic, and shortages or constrained supply can shift purchasing decisions toward manufacturers with dependable capacity. Differentiation may come from:

• Dual-source active pharmaceutical ingredient supply.
• Domestic or geographically diversified filling.
• Inventory held in multiple distribution centers.
• Validated alternate container suppliers.
• Low minimum order quantities.
• Contract terms supporting hospital continuity.

Supply reliability can produce more commercial value than a narrow formulation patent when hospital contracts are awarded through group purchasing organizations.

Combination and portfolio opportunities

A manufacturer with injectable cephalosporin capacity could use the same platform for other products, subject to compatibility and regulatory requirements. Potential portfolio expansion may include other beta-lactam antibiotics, premixed dextrose products, saline-based presentations, and pharmacy bulk packages.

The principal constraint is that each active ingredient requires separate stability, compatibility, sterility, container, and regulatory data. A shared manufacturing platform creates efficiency but does not automatically create a shared approval pathway.

How does ceftazidime and dextrose compare with competing injectable antibiotic products?

Ceftazidime competes with other hospital-administered beta-lactams and antipseudomonal agents. The relevant comparison is not limited to antimicrobial spectrum. Procurement teams also consider dosing frequency, reconstitution burden, stability, shortages, price, and susceptibility patterns.

Product category	Main commercial comparison
Ceftazidime injection	Established antipseudomonal cephalosporin; opportunity in premixed delivery
Cefepime injection	Broad hospital use and strong generic competition
Piperacillin/tazobactam	Different spectrum and combination profile; often supplied in premixed systems
Meropenem injection	Higher-value broad-spectrum product with different stability and cost profile
Ceftazidime/avibactam	Branded or specialty-resistant-infection product; materially different pricing and patent profile
Other cephalosporin premixes	Comparable operational value but different clinical positioning

Ceftazidime and dextrose can compete effectively where clinicians already select ceftazidime and hospitals want to reduce manipulation. It is less likely to displace a different antibiotic solely through packaging.

What FDA regulatory issues affect development?

The product must comply with sterile injectable requirements for identity, strength, quality, purity, sterility, endotoxins, particulate matter, container closure, and stability. The regulatory package should address:

• Drug substance and impurity controls.
• Dextrose grade and bioburden.
• Water-for-injection quality.
• Aseptic processing or terminal sterilization justification.
• Container-closure integrity.
• Extractables and leachables.
• Infusion-set compatibility.
• Labeling for storage and use.
• In-use stability.
• Shipping excursions.
• Visual inspection and particulate limits.

Dextrose can participate in chemical reactions under heat or alkaline conditions. The manufacturing process should therefore control exposure to elevated temperature and avoid unnecessary hold times. The compounding sequence, filtration strategy, filling temperature, and sterilization approach should be developed as an integrated process rather than selected independently.

What generic launch risks exist?

The largest launch risks are technical and operational:

1. Failure to achieve a commercially useful shelf life.
2. Color change or degradation during temperature excursions.
3. Container interaction or leachables.
4. Incompatibility with common infusion equipment.
5. Excessive manufacturing cost for a low-margin generic.
6. Inadequate supply of qualified ceftazidime API.
7. FDA questions on formulation similarity or stability.
8. Hospital reluctance to adopt a new container format.
9. Competition from established premixed products.
10. Failure to demonstrate a meaningful workflow or storage advantage.

A standard vial can reach market with lower development risk but weaker differentiation. A ready-to-use bag can create stronger commercial value but requires more demanding stability, container, manufacturing, and customer-validation work.

What licensing deals are relevant to the opportunity?

Licensing value is most likely to arise from:

• A patented premixed formulation.
• A proprietary multilayer bag.
• A validated dual-chamber container.
• A contract manufacturing arrangement.
• Regional commercialization rights.
• Hospital or group purchasing distribution.
• A technology license for extended room-temperature stability.

A license covering only the ceftazidime molecule has little strategic value because the compound is long genericized. A license covering a container, process, or stability platform can have value if it reduces development time or enables a regulatory claim that competitors cannot readily duplicate.

Key Takeaways

• Ceftazidime and dextrose is a mature small-molecule injectable opportunity with no meaningful original compound-patent barrier.
• The strongest value lies in ready-to-use presentation, extended stability, container performance, and supply reliability.
• The preferred excipient system is simple: ceftazidime, dextrose, water for injection, and tightly controlled pH adjustment.
• Preservatives and unnecessary buffer systems should generally be avoided in large-volume intravenous products.
• Formulation and container patents may be available, but broad claims covering ceftazidime in dextrose are likely difficult to defend.
• Paragraph IV risk is product-specific and depends on any later-listed formulation or delivery patents.
• Biosimilar competition is not relevant because ceftazidime is a chemically synthesized small molecule.
• A vial offers lower development complexity; a premixed bag offers greater operational differentiation.
• Manufacturing process controls, extractables data, and extended stability are central to FDA approval and commercial adoption.
• The most attractive commercial profile combines room-temperature stability, ready-to-use packaging, low preparation burden, and reliable supply.

FAQs

Is ceftazidime compatible with 5% dextrose?

Ceftazidime is labeled for dilution in compatible intravenous solutions, including dextrose injection, subject to concentration, storage, temperature, and administration conditions. Product-specific labeling and validated stability data control the permitted use period.

Can a new ceftazidime and dextrose product receive new-drug exclusivity?

A new presentation does not receive new-molecular-entity exclusivity merely because it uses a different vehicle or container. Any exclusivity depends on the approval pathway and the specific innovation presented to FDA.

Does dextrose improve ceftazidime stability?

Dextrose is primarily the vehicle and osmotic component. It does not inherently eliminate ceftazidime degradation. Stability depends on pH, temperature, concentration, oxygen exposure, container properties, and manufacturing conditions.

Is a premixed ceftazidime bag patentable?

A premixed bag may support patent claims directed to a defined composition, pH, concentration, stability period, container, or manufacturing process. Patentability depends on novelty, nonobviousness, enablement, and the prior art.

What is the best commercial differentiator for generic ceftazidime injection?

The strongest differentiators are usually validated room-temperature stability, ready-to-use packaging, low preparation burden, reliable supply, and compatibility with hospital inventory and infusion systems.

References

1. Food and Drug Administration. (2024a). Ceftazidime for injection prescribing information. U.S. Department of Health and Human Services.

2. Food and Drug Administration. (2024b). Q1A(R2) stability testing of new drug substances and products. U.S. Department of Health and Human Services.

3. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

4. International Council for Harmonisation. (2003). Q1A(R2): Stability testing of new drug substances and products. ICH.

5. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP Convention.